FindTrial
Sign In

The study of effect of Alfacalcidol treatment on Crohn's disease

The study of effect of Alfacalcidol treatment on Crohn's disease - The study of effect of Alfacalcidol treatment on Crohn's disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025961
Enrollment
31
Registered
2017-03-01
Start date
2017-05-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

Oral treatment of Alfacalcidol 1 microgram/day for 3 month

Sponsors

Nagoya University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Crohn's disease of ileocolic/colitis type Male and female over 18 year old Patient who has more than 220 in CDAI score written consent of participation for this study

Exclusion criteria

Exclusion criteria: Patient who has moderate to severe colitis Hypercalcemia Patient who is taking Calcium formulation,Vitamin D and Vitamin D analog Patient who is taking medicine including magnesium, digitalis, PTH formulation. Expectant and nursing mothers

Design outcomes

Primary

MeasureTime frame
Improvement rate on endoscopic score after 3 month.—

Secondary

MeasureTime frame
Improvement rate on clinical score comparison of endoscopic score, clinical score, biomarker between before and after treatment—

Countries

Japan

Contacts

Public ContactTsunaki Sawada

Nagoya University Hospital Department of Gastroenterology and Hepatology

t.sawada@med.nagoya-u.ac.jp0527442172

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026